Format
Items per page
Sort by

Send to:

Choose Destination

Links from

Items: 1 to 20 of 90

1.

[Leukemia: recent progress in diagnosis and treatment. Topics: III. Diagnosis and treatments; 4. Diagnosis and treatment of chronic myeloid leukemia].

Kimura S.

Nihon Naika Gakkai Zasshi. 2013 Jul 10;102(7):1712-9. Review. Japanese. No abstract available.

PMID:
23947233
2.

First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate.

Eskazan AE, Ayer M, Kantarcioglu B, Arica D, Demirel N, Aydin D, Yalniz FF, Elverdi T, Salihoglu A, Ar MC, Ongoren Aydin S, Baslar Z, Aydin Y, Tuzuner N, Ozbek U, Soysal T.

Br J Haematol. 2014 Oct;167(1):139-41. doi: 10.1111/bjh.12937. Epub 2014 May 10. No abstract available.

PMID:
24815307
3.

High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients--final analysis of a randomized, multicenter, phase III trial.

Petzer AL, Fong D, Lion T, Dyagil I, Masliak Z, Bogdanovic A, Griskevicius L, Lejniece S, Goranov S, Gercheva L, Stojanovic A, Peytchev D, Tzvetkov N, Griniute R, Stanchev A, Grubinger T, Kwakkelstein M, Schuld P, Gastl G, Wolf D.

Haematologica. 2012 Oct;97(10):1562-9. doi: 10.3324/haematol.2011.060087. Epub 2012 Apr 17.

5.

Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era.

Iqbal Z, Aleem A, Iqbal M, Naqvi MI, Gill A, Taj AS, Qayyum A, ur-Rehman N, Khalid AM, Shah IH, Khalid M, Haq R, Khan M, Baig SM, Jamil A, Abbas MN, Absar M, Mahmood A, Rasool M, Akhtar T.

PLoS One. 2013;8(2):e55717. doi: 10.1371/journal.pone.0055717. Epub 2013 Feb 8.

6.

Philadelphia-negative secondary acute myeloid leukaemia during imatinib treatment for chronic phase chronic myeloid leukaemia.

Ross DM, Jackson SR, Browett PJ.

Leuk Lymphoma. 2007 Jun;48(6):1231-3. No abstract available.

PMID:
17577792
7.

Safety and efficacy of nilotinib in chronic phase chronic myeloid leukemia in a patient with Wolf-Parkinson-White disease and hematological resistance after suboptimal response to imatinib at six months.

Cannella L, Breccia M, Loglisci G, Federico V, Santopietro M, Alimena G.

Acta Oncol. 2010 Apr;49(3):399-400. doi: 10.3109/02841860903521129. No abstract available.

PMID:
20105089
8.

Even better kinase inhibitors for chronic myeloid leukemia.

Sawyers CL.

N Engl J Med. 2010 Jun 17;362(24):2314-5. doi: 10.1056/NEJMe1004430. Epub 2010 Jun 5. No abstract available.

PMID:
20525994
9.

Imatinib therapy for patients with chronic myelogenous leukemia: are patients living longer?

DeAngelo DJ, Ritz J.

Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):1-3. No abstract available.

10.

[Chronic myeloid leukemia and imatinib mesylate therapy].

Chrobák L.

Vnitr Lek. 2004 Jan;50(1):10-2. Czech. No abstract available.

PMID:
15015223
11.

Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group.

Cervantes F, López-Garrido P, Montero MI, Jonte F, Martínez J, Hernández-Boluda JC, Calbacho M, Sureda A, Pérez-Rus G, Nieto JB, Pérez-López C, Román-Gómez J, González M, Pereira A, Colomer D.

Haematologica. 2010 Aug;95(8):1317-24. doi: 10.3324/haematol.2009.021154. Epub 2010 Mar 10.

12.

Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies.

Neelakantan P, Gerrard G, Lucas C, Milojkovic D, May P, Wang L, Paliompeis C, Bua M, Reid A, Rezvani K, O'Brien S, Clark R, Goldman J, Marin D.

Blood. 2013 Apr 4;121(14):2739-42. doi: 10.1182/blood-2012-11-466037. Epub 2013 Feb 4.

13.

First-line treatment with imatinib mesylate in patients with chronic phase chronic myeloid leukemia: experience of a public hospital in a developing country of South America.

da Silveira CA, Ferrari I.

Leuk Lymphoma. 2012 Jul;53(7):1417-9. doi: 10.3109/10428194.2011.653641. Epub 2012 Jan 31. No abstract available.

PMID:
22204455
14.

Chronic myelogenous leukemia with mild basophilia as the predominant manifestation at presentation.

Yasuda H, Aritaka N, Ando J, Hirama M, Komatsu N, Hirano T.

Intern Med. 2011;50(5):501-2. Epub 2011 Mar 1.

15.

Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study.

Corm S, Roche L, Micol JB, Coiteux V, Bossard N, Nicolini FE, Iwaz J, Preudhomme C, Roche-Lestienne C, Facon T, Remontet L.

Blood. 2011 Oct 20;118(16):4331-7. doi: 10.1182/blood-2011-01-330332. Epub 2011 Aug 17.

16.

Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.

Brave M, Goodman V, Kaminskas E, Farrell A, Timmer W, Pope S, Harapanhalli R, Saber H, Morse D, Bullock J, Men A, Noory C, Ramchandani R, Kenna L, Booth B, Gobburu J, Jiang X, Sridhara R, Justice R, Pazdur R.

Clin Cancer Res. 2008 Jan 15;14(2):352-9. doi: 10.1158/1078-0432.CCR-07-4175.

17.

Blood consult: high Sokal risk chronic myeloid leukemia and suboptimal response.

Roy L, Tomowiak C, Guilhot F.

Blood. 2011 Nov 10;118(19):5096-8. doi: 10.1182/blood-2011-03-335588. Epub 2011 Aug 29. No abstract available.

18.

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM; ENESTnd Investigators.

N Engl J Med. 2010 Jun 17;362(24):2251-9. doi: 10.1056/NEJMoa0912614. Epub 2010 Jun 5.

19.

High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group.

Thielen N, van der Holt B, Verhoef GE, Ammerlaan RA, Sonneveld P, Janssen JJ, Deenik W, Falkenburg JH, Kersten MJ, Sinnige HA, Schipperus M, Schattenberg A, van Marwijk Kooy R, Smit WM, Chu IW, Valk PJ, Ossenkoppele GJ, Cornelissen JJ.

Ann Hematol. 2013 Aug;92(8):1049-56. doi: 10.1007/s00277-013-1730-4. Epub 2013 Apr 10.

PMID:
23572137
20.

Chronic myeloid leukemia arising from acute myeloid leukemia: response to imatinib mesylate with favorable outcome.

Xu XH, Huang LS, Yang J, Yu T, Tong JF, Yuan XG, Zhao XY.

Leuk Lymphoma. 2013 Jan;54(1):195-7. doi: 10.3109/10428194.2012.692788. Epub 2012 Jun 13. No abstract available.

PMID:
22574970
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk